Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset

• Published in: Cardiology and Therapy Vol. 13; no. 2; pp. 315 - 339
• Main Authors: Channick, Richard, Chin, Kelly M., McLaughlin, Vallerie V., Lammi, Matthew R., Zamanian, Roham T., Turricchia, Stefano, Ong, Rose, Mitchell, Lada, Kim, Nick H.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.06.2024; Springer; Adis, Springer Healthcare
• Subjects: Cardiology; Care and treatment; Connective tissue disease; Internal Medicine; Macitentan; Medicine; Medicine & Public Health; Mixed connective tissue disease; NCT; NCT02126943; NCT03197688; Original Research; Patient outcomes; Pulmonary arterial hypertension; Pulmonary hypertension; Real-world evidence; Scleroderma; United States; Connective tissue disease; Macitentan; Systemic lupus erythematosus; Systemic sclerosis; Pulmonary arterial hypertension; Mixed connective tissue disease; Scleroderma; Real-world evidence

Introduction Data on real-world clinical practice and outcomes of patients with pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH) are scarce. The OPUS/OrPHeUS studies enrolled patients newly initiating macitentan, including those with CTD-PAH. This analysis describe...